Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)
Not Applicable
Completed
- Conditions
- -I87I87
- Registration Number
- PER-056-04
- Lead Sponsor
- BAYER S.A.,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients with acute symptomatic proximal deep vein thrombosis.
Men or women over 18 years of age.
Exclusion Criteria
Contraindication to comparator drugs
Symptomatic Pulmonary embolism
Conditions with increased bleeding risk
Unstable patients with reduced life expectancy
Severe renal impairment
Impaired liver function
Strong CYP 3A4 inhibitors
Platelet aggregation inhibitors (exception: ASA up to 500mg) therapy with anticoagulants or fibrinolytics
NSAIDs with half-life > 17 hours
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method